High PD-L1 Expression is Aassociated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy

被引：0
|
作者：
Lee, S. H. [1 ]
Chang, B. [1 ]
Yoon, B. W. [2 ]
机构：
[1] Kyung Hee Univ Hosp, Dept Internal Med, Seoul, South Korea
[2] Seoul Paik Hosp, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
programmed death-ligand 1; epidermal growth factor receptor mutation; T790M;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.56
引用
收藏
页码：S611 / S612
页数：2
相关论文
共 50 条
  • [1] High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Yoon, Byung Woo
    Chang, Boksoon
    Lee, Seung Hyeun
    ONCOTARGETS AND THERAPY, 2020, 13 : 8273 - 8285
  • [2] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Lee, S. H.
    Park, M. J.
    Chang, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S572 - S572
  • [3] Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs
    Jeon, W.
    Lim, B.
    Han, S.
    Kwack, W.
    Chang, B.
    Choi, H.
    Kim, Y.
    Choi, C.
    Park, M.
    Yoo, J.
    Lee, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs
    Lee, Seung Hyeun
    Park, Myung Jae
    Chang, Boksoon
    CANCER RESEARCH, 2019, 79 (13)
  • [5] High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
    Lee, S. H.
    Sung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S932 - S932
  • [6] High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Sung, Ji-Youn
    Park, Dong-Won
    Lee, Seung-Hyeun
    BIOMEDICINES, 2022, 10 (09)
  • [7] Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma
    Slomka, Jeremy
    Berthou, Hugo
    Mansuet-Lupo, Audrey
    Blons, Helene
    Fabre, Elizabeth
    Lerner, Ivan
    Rance, Bastien
    Alifano, Marco
    Chapron, Jeanne
    Birsen, Gary
    Gibault, Laure
    Arrondeau, Jennifer
    Leroy, Karen
    Wislez, Marie
    PLOS ONE, 2024, 19 (11):
  • [8] High tumor mutation burden predicts unfavorable clinical outcome in EGFR-mutated lung adenocarcinoma treated with targeted therapy.
    Lee, Seung Hyeun
    Sung, Ji-Youn
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma
    Kunimasa, Kei
    Hirotsu, Yosuke
    Amemiya, Kenji
    Honma, Keiichiro
    Nakamura, Harumi
    Nishino, Kazumi
    Omata, Masao
    THORACIC CANCER, 2023, 14 (22) : 2210 - 2215
  • [10] Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in EGFR-mutated lung adenocarcinoma
    Ito, Atsushi
    Kano, Shu
    Tarukawa, Tomohito
    Suzuki, Yuta
    Sakaguchi, Tadashi
    Ito, Kentaro
    Nishii, Yoichi
    Taguchi, Osamu
    Yasui, Hiroki
    Takao, Motoshi
    Hataji, Osamu
    FRONTIERS IN ONCOLOGY, 2024, 14
12345